A Phase 2 interventional study of PF-00610355 and PF - 00610355 in Pulmonary Disease, Chronic Obstructive, Lung Diseases and Lung Diseases, Obstructive, sponsored by Pfizer. Completed at 75 sites in 12 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-06.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 405 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: PF-00610355
Drug: PF - 00610355
Drug: PF- 00610355
Drug: Placebo
Drug: Salmeterol
oral, inhaled, dry powder, 600ug, OD
oral, inhaled, dry powder, 300ug, OD
oral, inhaled, dry powder, 100ug, OD
oral, inhaled, dry powder, placebo, OD
salmeterol, 50ug, BID
Change from baseline in trough FEV1
Time frame: 6 week
Maximal and mean changes from baseline in heart rate, QTc and plasma potassium
Time frame: each visit
Change from baseline in peak FEV1
Time frame: 0-6 hours /6 weeks
Change from baseline in trough and peak FEV6, FVC and IC
Time frame: 6 weeks
Change from baseline in trough FEV1, FEV6, forced vital capacity (FVC) and inspiratory capacity (IC)
Time frame: 2 and 4 weeks
Change from baseline in Respiratory Questionnaire Self-Administered Standardised (CRQ-SAS)
Time frame: 2,4,6 weeks
Change from baseline of COPD symptoms and rescue bronchodilator use (per daily diary).
Time frame: weekly
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer